Oarsman Capital’s BioLife Solutions BLFS Stock Holding History

Oarsman Capital’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-451	Closed	-$11.7K	–	315
2024 Q4	$11.7K	Buy	451 +26	+6%	+$647	﹤0.01%	675
2024 Q3	$10.6K	Buy	+425	New	+$10K	﹤0.01%	697

Other funds holding BLFS

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Oarsman Capital's BLFS Position: Q1 2025 in Review

Oarsman Capital sold out of BioLife Solutions (BLFS) in Q1 2025, closing a stake of 451 shares — an estimated $11.7K sold.

Oarsman Capital first reported a position in BLFS in Q3 2024 and held it in 2 quarters. The position peaked at $11.7K in Q4 2024. 188 funds tracked by Wall St. Rank hold BLFS as of Q1 2025.

Oarsman Capital reported no remaining BioLife Solutions position as of Q1 2025 after selling out during the quarter.
Oarsman Capital sold 451 BioLife Solutions shares in Q1 2025, an estimated $11.7K.
Oarsman Capital first reported a position in BioLife Solutions in Q3 2024 and held it in 2 quarters.
Oarsman Capital's BioLife Solutions position peaked at $11.7K in Q4 2024.
188 funds tracked by Wall St. Rank held BioLife Solutions as of Q1 2025.

Based on Oarsman Capital's 13F filing for Q1 2025, filed 14 May 2025.